MNPR
$60.27
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
Recent News
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them.
Key Insights Institutions' substantial holdings in Monopar Therapeutics implies that they have significant influence...
Broadcom Stock Sees Improved Relative Strength Rating
In a welcome move, Broadcom stock saw its Relative Strength Rating improve from 70 to 79 on Monday. See if Broadcom stock can continue to show renewed price strength and clear that threshold. Is Broadcom Stock A Buy?
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Monopar Therapeutics fair value estimate is US$168 Monopar...
Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls
Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls